Benchmark Reiterates Hold Rating on VolitionRX (VNRX)

Benchmark analyst Bruce Jackson reiterated a Hold rating on VolitionRX (NYSE: VNRX).

The analyst commented, “VolitionRx anticipates making additional progress on its strategy to monetize its unique nucleosomic testing assets during 2025 through (1) completion of a licensing deal with a major invitro diagnostics company, (2) expanding the veterinary testing business with a feline indication and availability of high-speed, automated testing, and (3) the sale of CE-Mark IVD, IVD-D test kits, which they have already sold to three hospitals. The licensing deal could trigger a warrant exercise valued at roughly $7 million. The company received $1.8 million in grant funding during 1Q 2025 and could receive an additional $4-5M over the course of the year. The monetization efforts will be supported by additional clinical data on lung cancer testing, sepsis, and multi-cancer detection. We’ve updated the financial models accordingly and are maintaining our Hold rating on the shares. Completion of a licensing deal could be a significant event, the revenue from which we are treating as upside to our estimates.”

For an analyst ratings summary and ratings history on VolitionRX click here. For more ratings news on VolitionRX click here.

Shares of VolitionRX closed at $0.50 yesterday.

You May Also Be Interested In